Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways.

Autor: Bischof K; Department of Cancer Immunology, Institute for Cancer Research, University of Oslo, Norway.; Division of Cancer Medicine, Department of Gynecological Oncology, Oslo University Hospital, Norway., Cremaschi A; Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Norway.; Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Norway.; Singapore Institute for Clinical Sciences, A*STAR, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Eroukhmanoff L; Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Norway., Landskron J; Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Norway., Flage-Larsen LL; Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Norway., Gade A; Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Norway., Bjørge L; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, Centre for Cancer Biomarkers CCBIO, University of Bergen, Norway., Urbanucci A; Faculty of Medicine and Health Technology, TAYS Cancer Centre and FICAN Mid, Tampere University, Finland.; Department of Tumor Biology, Institute for Cancer Research, University of Oslo, Norway., Taskén K; Department of Cancer Immunology, Institute for Cancer Research, University of Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Norway.

Publikováno v: Molecular oncology [Mol Oncol] 2024 Sep 08. Date of Electronic Publication: 2024 Sep 08.